AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions

May 29, 2026 11:30 AM EDTUpdated 01:15 PM News Briefing As­traZeneca seeks path for failed an­ti­body; Imfinzi, Trem­fya get la­bel ex­pan­sions ENDPOINTS 🔎 As­traZeneca nar­rows path for failed an­ti­body: The com­pa­ny an­nounced last sum­mer that its mon­o­clon­al an­ti­body anse­lamimab missed the pri­ma­ry end­point … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER